Page last updated: 2024-09-05

sorafenib and LSM-2536

sorafenib has been researched along with LSM-2536 in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(LSM-2536)
Trials
(LSM-2536)
Recent Studies (post-2010) (LSM-2536)
6,5207305,251505

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)LSM-2536 (IC50)
kappa-type opioid receptor isoform 1Homo sapiens (human)0.0815
Kappa-type opioid receptorHomo sapiens (human)0.081

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y1

Reviews

1 review(s) available for sorafenib and LSM-2536

ArticleYear
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators

2022